Dr. Janice M. Mehnert on Immunotherapy vs BRAF/MEK Inhibitors in the Adjuvant Setting for Melanoma

June 13, 2019
Janice M. Mehnert, MD

Cancer Network spoke with Janice M. Mehnert, MD, of Rutgers Cancer Institute, about the use of immunotherapy vs BRAF/MEK inhibitors in the adjuvant setting for melanoma.

Cancer Network spoke with Janice M. Mehnert, MD, of Rutgers Cancer Institute, about the use of immunotherapy vs BRAF/MEK inhibitors in the adjuvant setting for melanoma.

Related Content:

ASCO Melanoma | Melanoma